← FDA Drug Approvals (Drugs@FDA)

CANAGLIFLOZIN

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: TEVA PHARMS USA · Approved 2022-06-14

Drug application

FDA Application #

ANDA210451

Application type

Abbreviated New Drug Application (Generic)

Brand name

CANAGLIFLOZIN

Generic name

Canagliflozin

Active ingredients

CANAGLIFLOZIN

Dosage form

TABLET

Route

ORAL

Marketing status

None (Tentative Approval)

Sponsor

TEVA PHARMS USA

First approval

2022-06-14

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown